Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Lung Cancer. 2017 Jul 18;111:108–115. doi: 10.1016/j.lungcan.2017.07.009

Figure 1.

Figure 1

Patient disposition

aIncludes 17 patients who received olaratumab monotherapy.

bAs of June 25, 2015.

P/C, paclitaxel/carboplatin; mITT, modified intent to treat; AE, adverse event; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; Symp. Det., symptomatic deterioration.